The spectrum of XXXX in American Indians.

@entity1 @entity8 @entity6 @entity740 @entity631 @entity454
American Indians and Alaska Natives (AI/AN) experience high rates of @entity740 . Several studies have demonstrated increased rates of early @entity8 among AI/AN, both in @entity6 and non- @entity6 . Among some tribes of the American Southwest, high rates of mesangiopathic @entity631 have been documented. The epidemic of @entity6 among AI/AN, which began in the middle of the 20th century, appears to be driving the increase in @entity454 ( @entity454 ). At the end of 1999, AI/AN had a national prevalence rate of treated @entity454 that was 3.5 times greater than that of white Americans. There is significant regional variation as well as differences among the approximately 550 tribes that make up the American Indian community, with some tribes experiencing @entity454 rates over twenty times the rate of whites. Although graft survival is excellent, AI/AN @entity454 @entity1 are less likely than whites to be placed on the transplant waiting list, and those listed wait longer for a transplant. Despite socioeconomic barriers and high rates of co-morbid illness, survival among AI/AN @entity454 @entity1 is better than among whites. The @entity8 , particularly the multigenerational occurrence in some families, is perceived as a major threat to the well-being of native communities. There is a sense of urgency among tribal leaders to address this epidemic, and research that may decrease its burden is likely to be welcomed.
